Aerosol and other novel administrations for prevention and treatment of invasive aspergillosis

References

• Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161–189
   PubMed Web of Science ®Google Scholar
• Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41: 1455–1460
   PubMed Web of Science ®Google Scholar
• Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43: S49–S58
   PubMed Web of Science ®Google Scholar
• Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transpl 2003; 22: 258–266
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–360
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Haas A, Cornely OA, et al. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67: 1567–1601
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Arthur RR, Drew RH, Perfect JR. Novel modes of antifungal drug administration. Expert Opin Investig Drugs 2004; 13: 903–932
   PubMed Web of Science ®Google Scholar
• Camarata PJ, Dunn DL, Farney AC, et al. Continual intracavitary administration of amphotericin B as an adjunct in the treatment of Aspergillus brain abscess: case report and review of the literature. Neurosurgery 1992; 31: 575–579
   PubMed Web of Science ®Google Scholar
• Camarata PJ, Dunn DL, Farney AC, et al. Continual intracavitary administration of amphotericin B as an adjunct in the treatment of Aspergillus brain abscess: case report and review of the literature. Neurosurgery 1992; 31: 575–579
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Kofla G, Otto K, et al. CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 2007; 21: 659–676
   PubMed Web of Science ®Google Scholar
• Stevens DA, Shatsky SA, Stevens DA, Shatsky SA. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin Respir Infect 2001; 16: 263–269
   PubMedGoogle Scholar
• Meunier-Carpentier F, Snoeck R, Gerain J, et al. Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia. N Engl J Med 1984; 311: 1056
   PubMed Web of Science ®Google Scholar
• Jeffery GM, Beard ME, Ikram RB, et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991; 90: 685–692
   PubMed Web of Science ®Google Scholar
• Trigg ME, Morgan D, Burns TL, et al. Successful program to prevent Aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin. Bone Marrow Transplant 1997; 19: 43–47
   PubMed Web of Science ®Google Scholar
• Todeschini G, Murari C, Bonesi R, et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur J Clin Micro Infect Dis 1993; 12: 614–618
   PubMed Web of Science ®Google Scholar
• Todeschini G, Murari C, Bonesi R, et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur J Clin Microbiol 1993; 12: 614–618
   Google Scholar
• Jorgensen CJ, Dreyfus F, Vaixeler J, et al. Failure of amphotericin B spray to prevent aspergillosis in granulocytopenic patients. Nouv Rev Fr Hematol 1989; 31: 327–328
   PubMedGoogle Scholar
• Min YG, Kim HS, Lee KS, et al. Aspergillus sinusitis: clinical aspects and treatment outcomes. Otolaryngol Head Neck Surg 1996; 115: 49–52
   PubMed Web of Science ®Google Scholar
• Kurnatowski P, Filipiak A, Kurnatowski P, Filipiak A. Otomycosis: prevalence, clinical symptoms, therapeutic procedure. Mycoses 2001; 44: 472–479
   PubMed Web of Science ®Google Scholar
• Kaur R, Mittal N, Kakkar M, et al. Otomycosis: a clinicomycologic study. Ear Nose Throat J 2000; 79: 606–609
   PubMedGoogle Scholar
• Gordon G, Giddings NA, Gordon G, Giddings NA. Invasive otitis externa due to Aspergillus species: case report and review. Clin Infect Dis 1994; 19: 866–870
   PubMed Web of Science ®Google Scholar
• Kintzel PE, Trausch DE, Copfer AL, et al. Otic administration of amphotericin B 0.25% in sterile water. Ann Pharmacother 1994; 28: 333–335
   PubMed Web of Science ®Google Scholar
• Paulose KO, Al Khalifa S, Shenoy P, et al. Mycotic infection of the ear (otomycosis): a prospective study. J Laryngol Otol 1989; 103: 30–35
   PubMed Web of Science ®Google Scholar
• Prasad N, Gupta A, Prasad N, Gupta A. Fungal peritonitis in peritoneal dialysis patients. Perit Dial Int 2005; 25: 207–222
   PubMed Web of Science ®Google Scholar
• van der Voort PH, Boerma EC, Yska JP, et al. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother 2007; 59: 952–956
   PubMed Web of Science ®Google Scholar
• Nannini EC, Paphitou NI, Ostrosky-Zeichner L. Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. Diagn Microbiol Infect Dis 2003; 46: 49–54
   PubMed Web of Science ®Google Scholar
• Manzano-Gayosso P, Hernandez-Hernandez F, Mendez-Tovar LJ, et al. Fungal peritonitis in 15 patients on continuous ambulatory peritoneal dialysis (CAPD). Mycoses 2003; 46: 425–429
   PubMed Web of Science ®Google Scholar
• Ide L, De Laere E, Verlinde A, Surmont I. A case of Aspergillus fumigatus peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD): diagnostic and therapeutic challenges. J Clin Pathol 2005; 58: 559
   PubMed Web of Science ®Google Scholar
• Callanan D, Scott IU, Murray TG, et al. Early onset endophthalmitis caused by Aspergillus species following cataract surgery. Am J Ophthalmol 2006; 142: 509–511
   PubMed Web of Science ®Google Scholar
• Weishaar PD, Flynn HW, Murray TG, et al. Endogenous Aspergillus endophthalmitis – Clinical features and treatment outcomes. Ophthalmology 1998; 105: 57–65
   PubMed Web of Science ®Google Scholar
• Zarkovic A, Guest S, Zarkovic A, Guest S. Scedosporium apiospermum traumatic endophthalmitis successfully treated with voriconazole. Int Ophthalmol 2007; 27: 391–394
   PubMedGoogle Scholar
• Chen FK, Chen SD, Tay-Kearney ML, et al. Intravitreal voriconazole for the treatment of endogenous endophthalmitis caused by Scedosporium apiospermum. Clin Experiment Ophthalmol 2007; 35: 382–385
   PubMed Web of Science ®Google Scholar
• Shen YC, Wang MY, Wang CY, et al. Clearance of intravitreal voriconazole. Invest Ophthalmol Vis Sci 2007; 48: 2238–2241
   PubMed Web of Science ®Google Scholar
• Sen P, Gopal L, Sen PR, et al. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006; 26: 935–939
   PubMed Web of Science ®Google Scholar
• Kramer M, Kramer MR, Blau H, et al. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006; 113: 1184–1186
   PubMed Web of Science ®Google Scholar
• Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol 2004; 122: 1687–1692
   PubMedGoogle Scholar
• Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122: 42–47
   PubMed Web of Science ®Google Scholar
• FlorCruz, NV, Peczon, I, Jr. Medical interventions for fungal keratitis. Cochrane Database of Systematic Reviews. 2008; Issue 1. Art. No.: CD004241. DOI: 10.1002/14651858.CD004241.pub2.
   PubMed Web of Science ®Google Scholar
• Thiel MA, Zinkernagel AS, Burhenne J, et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007; 51: 239–244
   PubMed Web of Science ®Google Scholar
• Tu EY, McCartney DL, Beatty RF, et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143: 222–227
   PubMed Web of Science ®Google Scholar
• Tu EY, Park AJ. Recalcitrant Beauveria bassiana keratitis-confocal microscopy findings and treatment with posaconazole (Noxafil). Cornea 2007; 26: 1008–1010
   PubMed Web of Science ®Google Scholar
• Galarreta DJ, Tuft SJ, Ramsay A, Dart JKG. Fungal keratitis in London-microbiological and clinical evaluation. Cornea 2007; 26: 1082–1086
   PubMed Web of Science ®Google Scholar
• Knechtel SA, Klepser ME, Knechtel SA, Klepser ME. Safety of aerosolized amphotericin B. Expert Opin Drug Safety 2007; 6: 523–532
   PubMed Web of Science ®Google Scholar
• Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 2006; 27(Suppl. 1)36–44
   PubMedGoogle Scholar
• Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93: 3654–3661
   PubMed Web of Science ®Google Scholar
• Conneally E, Cafferkey M, Daly P, et al. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990; 5: 403–406
   PubMed Web of Science ®Google Scholar
• Erjavec Z, Woolthuis G, Vries-Hospers H, et al. Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol 1997; 16: 364–368
   Google Scholar
• Behre GF, Schwartz S, Lenz K, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995; 71: 287–291
   PubMed Web of Science ®Google Scholar
• Hertenstein B, Kern W, Schmeiser T, et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994; 68: 21–26
   PubMed Web of Science ®Google Scholar
• Calvo V, Borro J, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999; 115: 1301–1304
   PubMed Web of Science ®Google Scholar
• Monforte V. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung transplanted patients. Transplantation 2003; 75: 1571–1574
   PubMed Web of Science ®Google Scholar
• Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627–628
   PubMed Web of Science ®Google Scholar
• Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20: 1274–1281
   PubMed Web of Science ®Google Scholar
• Roth C, Gebhart J, Just-Nubling G, et al. Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis. Infection 1996; 24: 354–360
   PubMed Web of Science ®Google Scholar
• Allen SD, Sorensen KN, Nejdl MJ, et al. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994; 34: 1001–1013
   PubMed Web of Science ®Google Scholar
• Cicogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 259–261
   PubMed Web of Science ®Google Scholar
• Gilbert BE. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med-Deposition Clearance Effects Lung 1996; 9: 111–122
   PubMedGoogle Scholar
• Lambros MP, Bourne DW, Abbas SA, Johnson DL. Disposition of aerosolized liposomal amphotericin B. J Pharm Sci 1997; 86: 1066–1069
   PubMed Web of Science ®Google Scholar
• Ruijgrok EJ, Vulto AG, Etten EW. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J Pharm Pharmacol 2000; 52: 619–627
   PubMed Web of Science ®Google Scholar
• Ruijgrok EJ, Vulto AG, Etten EW. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 2001; 48: 89–95
   PubMed Web of Science ®Google Scholar
• Drew RH, Dodds AE, Benjamin DK, Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232–237
   PubMed Web of Science ®Google Scholar
• Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545–548
   PubMed Web of Science ®Google Scholar
• Alexander BD, Dodds Ashley ES, Addison RM, et al. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transplant Infect Dis 2006; 8: 13–20
   PubMed Web of Science ®Google Scholar
• Monforte, V (2004) , Gavalda, J, Roman, A. , et al. Pharmacokinetics and efficacy of nebulized Ambisome in lung transplantation. 44th Interscience Conference of Antimicrobial Agents and Chemotherapy; 30, October – 2, November, 2004; Washington, DC, Abstract M-1042, .
   Google Scholar
• Rijnders, BJ (2006) , Slobbe, L. Aerosolised liposomal amphoB to prevent invasive aspergillosis during prolonged neutropenia: randomized placebo controlled trial. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27–30, September, 2006; San Francisco, California Abstract M-1308c, .
   Google Scholar
• Ruiz, I, Molina, I, Gavalda, J, , et al. Safety and tolerability of nebulized liposomal amphotericin B in hematologic patients (abstract). Proceedings and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 16–19, December, Washington, DC, 2005.
   Google Scholar
• Ruijgrok EJ, Fens MHA, Bakker-Woudenberg IA, et al. Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50: 1852–1854
   PubMed Web of Science ®Google Scholar
• Gavalda J, Martin MT, Lopez P, et al. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 2005; 49: 3028–3030
   PubMed Web of Science ®Google Scholar
• Dalconte I, Riva G, Obert R, et al. Tracheobronchial aspergillosis in a patient with AIDS treated with aerosolized amphotericin B combined with itraconazole. Mycoses 1996; 39: 371–374
   PubMed Web of Science ®Google Scholar
• Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) 1996; 75: 142–156
   PubMed Web of Science ®Google Scholar
• Purcell IF, Corris PA. Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax 1995; 50: 1321–1323
   PubMed Web of Science ®Google Scholar
• Ruffini E, Baldi S, Rapellino M, et al. Fungal infections in lung transplantation. Incidence, risk factors and prognostic significance. Sarcoidosis Vasc 2001; 18: 181–190
   PubMed Web of Science ®Google Scholar
• Safdar A, O'Brien S, Kouri IF. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 2004; 34: 467–468
   PubMed Web of Science ®Google Scholar
• Beyer J, Schwartz S, Barzen G, et al. Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection 1994; 22: 143–148
   PubMed Web of Science ®Google Scholar
• Dubois J, Bartter T, Gryn J, Pratter M. The physiologic effects of inhaled amphotericin B. Chest 1995; 108: 750–753
   PubMed Web of Science ®Google Scholar
• Gryn J, Goldberg J, Johnson E, et al. The toxicity of daily inhaled amphotericin B. Am J Clin Oncol 1993; 16: 43–46
   PubMed Web of Science ®Google Scholar
• Gallagher, J, Ashley, E, Howell, D, , et al. Foamy macrophages in bronchoalveolar lavage fluid from lung transplant recipients receiving aersolized formulations of amphotericin B (abstract). Proceedings and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 30, October – 2, November, Washington, DC, 2004.
   Google Scholar
• Perfect JR, Dodds AE, Drew R. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis 2004; 39(Suppl. 4)S207–S210
   Google Scholar
• Marra F, Partovi N, Wasan K, et al. Amphotericin B disposition after aerosol inhalation in lung transplant recipients. Ann Pharmacother 2002; 36: 46–51
   PubMed Web of Science ®Google Scholar
• Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006; 6: 2765–2773
   PubMed Web of Science ®Google Scholar
• Ashley, ED, Petry, N, Davies, JD, , et al. Aerosolized amphotericin B lipid complex distribution in lung transplant recipients: a comparison of continuous versus breath-actuated nebulizers. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, 17–20, September, Chicago, IL. 2007. (abstract M1165).
   Google Scholar
• Diot P, Rivoire B, Le Pape A, et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J 1995; 8: 1263–1268
   PubMed Web of Science ®Google Scholar